Cargando…

The Timing of Surgery Following Stereotactic Body Radiation Therapy Impacts Local Control for Borderline Resectable or Locally Advanced Pancreatic Cancer

SIMPLE SUMMARY: The role of radiation therapy in localized pancreatic cancer is controversial. The interval of time from the end of radiotherapy to surgery has been shown in some cancer disease sites to affect subsequent outcomes but has not been studied in pancreatic cancer. We aimed to characteriz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Timothy, Reddy, Abhinav, Hill, Colin, Sehgal, Shuchi, He, Jin, Zheng, Lei, Herman, Joseph, Meyer, Jeffrey, Narang, Amol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954439/ https://www.ncbi.nlm.nih.gov/pubmed/36831594 http://dx.doi.org/10.3390/cancers15041252

Ejemplares similares

Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemotherapy and stereotactic body radiotherapy followed by surgical resection
por: Reddy, Abhinav V., et al.
Publicado: (2021)

Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy
por: Reddy, Abhinav V., et al.
Publicado: (2021)

Upfront Chemotherapy Followed by Stereotactic Body Radiation Therapy with or without Surgery in Older Patients with Localized Pancreatic Cancer: A Single Institution Experience and Review of the Literature
por: Reddy, Abhinav V., et al.
Publicado: (2022)

High local failure rates despite high margin‐negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi‐agent chemotherapy
por: Hill, Colin, et al.
Publicado: (2022)

Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy
por: Reddy, Abhinav V., et al.
Publicado: (2022)

A safety study of intraoperative radiation therapy following stereotactic body radiation therapy and multi-agent chemotherapy in the treatment of localized pancreatic adenocarcinoma: study protocol of a phase I trial
por: Reddy, Abhinav V., et al.
Publicado: (2022)

Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity
por: Hill, Colin S., et al.
Publicado: (2022)

Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer
por: Rajagopalan, Malolan S, et al.
Publicado: (2013)

Inter-Breath-Hold Geometric and Dosimetric Variations in Organs at Risk during Pancreatic Stereotactic Body Radiotherapy: Implications for Adaptive Radiation Therapy
por: Hooshangnejad, Hamed, et al.
Publicado: (2023)

Stereotactic body radiation therapy for locally advanced pancreatic cancer
por: Jung, Jinhong, et al.
Publicado: (2019)

Geometric Reproducibility of Fiducial Markers and Efficacy of a Patient-Specific Margin Design Using Deep Inspiration Breath Hold for Stereotactic Body Radiation Therapy for Pancreatic Cancer
por: Han-Oh, Sarah, et al.
Publicado: (2021)

Survival outcome after stereotactic body radiotherapy for locally advanced and borderline resectable pancreatic cancer: A systematic review and meta-analysis
por: Liu, Shi, et al.
Publicado: (2021)

Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial
por: Zheng, Rong, et al.
Publicado: (2020)

The borderline resectable and locally advanced pancreatic ductal adenocarcinoma: Definition
por: Soweid, Assaad M.
Publicado: (2017)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Stereotactic body radiation therapy for palliative management of pancreatic adenocarcinoma in elderly and medically inoperable patients
por: Ryan, John F., et al.
Publicado: (2018)

Stereotactic Body Radiation Therapy for Locally Progressive and Recurrent Pancreatic Cancer after Prior Radiation
por: Sutera, Philip, et al.
Publicado: (2018)

The borderline resectable/locally advanced pancreatic ductal adenocarcinoma: EUS oriented
por: Iordache, Sevastiţa, et al.
Publicado: (2017)

Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
por: Alva-Ruiz, Roberto, et al.
Publicado: (2021)

Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy
por: Cheng, Zhi, et al.
Publicado: (2018)

Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer
por: Jung, Jae Hyup, et al.
Publicado: (2022)

Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
por: Tsujimoto, Akiko, et al.
Publicado: (2019)

A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma
por: Paiella, Salvatore, et al.
Publicado: (2021)

Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma
por: Koong, Amanda J., et al.
Publicado: (2017)

Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas
por: Lominska, Chris E, et al.
Publicado: (2012)

The borderline resectable/locally advanced pancreatic ductal adenocarcinoma: What should be the surgeon's choice?
por: Zerbi, Alessandro, et al.
Publicado: (2017)

Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
por: Sulciner, Megan L., et al.
Publicado: (2022)

Neoadjuvant chemotherapy and radiotherapy outcomes in borderline‐resectable and locally‐advanced pancreatic cancer patients
por: Botta, Gregory P., et al.
Publicado: (2022)

Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer
por: Gemenetzis, Georgios, et al.
Publicado: (2021)

A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma
por: Crocenzi, Todd, et al.
Publicado: (2016)

Stereotactic body radiation therapy for the primary treatment of localized prostate cancer
por: Oliai, Caspian, et al.
Publicado: (2012)

ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer—Resection Cuts the Deal
por: Eshmuminov, Dilmurodjon, et al.
Publicado: (2023)

Prospective analysis of different combined regimens of stereotactic body radiation therapy and chemotherapy for locally advanced pancreatic cancer
por: Zhu, Xiaofei, et al.
Publicado: (2018)

Role of stereotactic body radiation in the enhancement of the quality of life in locally advanced pancreatic adenocarcinoma: a systematic review
por: Vornhülz, Marlies, et al.
Publicado: (2022)

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
por: Hosein, Peter J, et al.
Publicado: (2012)

Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX
por: Choi, Young Hoon, et al.
Publicado: (2021)

Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection
por: Ji, Xiaoqin, et al.
Publicado: (2022)

Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer
por: Wu, Guangyin, et al.
Publicado: (2019)

Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer
por: Kwon, Jung Hyun, et al.
Publicado: (2010)

Local failure and vertebral body fracture risk using multifraction stereotactic body radiation therapy for spine metastases
por: Mehta, Nihaal, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8rji4kcstiud0rapbnher0hhms